Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price target of p1,500.00. The company’s shares closed yesterday ...

limited upside in pipeline catalysts and 2025 estimates “makes it increasingly challenging for us to recommend that investors put new money to work in GSK until pipeline visibility improves ...

The company has made significant progress in its pipeline, with 11 positive Phase III readouts and plans for five major new product approvals next year. GSK PLC (NYSE:GSK) successfully resolved ...

GSK further contends that Moderna got its hands on technical know-how tied to the company’s mRNA vaccine platform by “hiring several former Novartis and GSK employees with first-hand knowledge.” ...

Legalcategory GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln October 9, 2024 Healthcare & Pharmaceuticalscategory GSK, Pfizer RSV vaccine sales fall in US as millions fewer ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative ...

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) have announced a new collaboration with the global biopharma company GSK to ...

GlaxoSmithKline is under pressure from shareholders ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA editing in humans. The update on the GSK-partnered prospect sent Wave’s ...

Also Read: GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement. Over half of all women are affected by uUTIs in their lifetime, with approximately 30% suffering from recurrent disease. New ...